Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brinzolamide

FDA-approved product (suspension/drops, ophthalmic), marketed as Azopt, Brinzolamide.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brinzolamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
FDA pharmacologic class
Carbonic Anhydrase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis83.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Brinzolamide in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brinzolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

    NCT00758342 · start 2006-05

    Registered record
    Registry ID
    NCT00758342
    Conditions
    Intraocular Pressure
    Interventions
    Travoprost 0.004% + Brinzolamide 1.0%; Travoprost 0.004% + Tears Natural
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2006-05
    Completion
    2008-03
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraocular Pressure
    InterventionTravoprost 0.004% + Brinzolamide 1.0%; Travoprost 0.004% + Tears Natural
    PhasePhase 4
    Registry statusTerminated

  • A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

    NCT00314158 · start 2005-11

    Registered record
    Registry ID
    NCT00314158
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension; Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension; Timolol 5 mg/ml eye drops, solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11
    Completion
    2007-01
    Enrolment
    523

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension; Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension; Timolol 5 mg/ml eye drops, solution
    PhasePhase 3
    Registry statusCompleted

  • Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension

    NCT00372827 · start 2004-02

    Registered record
    Registry ID
    NCT00372827
    Conditions
    Primary Open-angle Glaucoma; Ocular Hypertension; Pigment Dispersion Glaucoma
    Interventions
    Brinzolamide 1% added to Travoprost 0.004%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-02
    Completion
    2006-01
    Enrolment
    245

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open-angle Glaucoma; Ocular Hypertension; Pigment Dispersion Glaucoma
    InterventionBrinzolamide 1% added to Travoprost 0.004%
    PhasePhase 4
    Registry statusCompleted

  • Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

    NCT00121147 · start 2003-09

    Registered record
    Registry ID
    NCT00121147
    Conditions
    Open Angle Glaucoma; Ocular Hypertension; Pseudoexfoliation Syndrome
    Interventions
    Travatan; Azopt; Alphagan P
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension; Pseudoexfoliation Syndrome
    InterventionTravatan; Azopt; Alphagan P
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension

    NCT00061516 · start 2003-01

    Registered record
    Registry ID
    NCT00061516
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    BETAXON (levobetaxolol HCl); AZOPT (brinzolamide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2006-02
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionBETAXON (levobetaxolol HCl); AZOPT (brinzolamide)
    PhasePhase 3
    Registry statusCompleted